Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Puthanakit, Thanyawee ^a,b   van der Lugt, Jasper ^a,c   Bunupuradah, Torsak ^a   Ananworanich, Jintanat ^a,d   Gorowara, Meena ^a   Phasomsap, Chayapa ^a   Jupimai, Thidarat ^a   Boonrak, Pitch ^a   Pancharoen, Chitsanu ^b   Burger, David ^e   Ruxrungtham, Kiat ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c International Antiretroviral Trial Evaluation Centre   (Netherlands)

^d South East Asia Research Collaboration with University of Hawaii ^*  (Thailand)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Protease inhibitors; Second line treatment; Therapeutic drug monitoring

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VIRUS LOAD; BLOOD; CHEMISTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; PLASMA; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; PLASMA; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 73949117004     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp322     Document Type: Article

References (27)

1. Eshleman SH, Hoover DR, Chen S et al. Resistance after singledose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19: 2167-9.
2. World Health Organization. WHO Antiretroviral Therapy for Infants and Children 2008. Geneva, Switzerland: World Health Organization, 10-11 April 2008. http://www.who.int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_m report_2008.pdf (1 March 2009, date last accessed).
3. Gutierrez F, Padilla S, Navarro A et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003; 33: 594-600.
4. Avihingsanon A, van der Lugt J, Kerr S et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2008; 85: 402-8.
5. Autar RS, Boffito M, Hassink E et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56: 908-13.
6. Ananworanich J, Gayet-Ageron A, Ruxrungtham K et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008; 13: 375-80.
7. Boyd M, Mootsikapun P, Burger D et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10: 301-7.
8. van der Lugt J, Autar RS, Ubolyam S et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008; 61: 1145-53.
9. Bergshoeff AS, Fraaij PL, van Rossum AM et al. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2004; 48: 1904-7.
10. Plipat N, Cressey TR, Vanprapar N et al. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2007; 26: 86-8.
11. Ananworanich J, Kosalaraksa P, Hill A et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24: 874-9.
12. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization, 7 August 2006. http://www.who.int/hiv/pub/guidelines/en/ (1 March 2009, date last accessed).
13. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0, December 2004. http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/ DAIDSAEGradingTable.pdf (1 March 2009, date last accessed).
14. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
15. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
16. Breilh D, Pellegrin I, Rouzes A et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18: 1305-10.
17. Lal R, Hsu A, Granneman G, El-Shourbagy et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. In: Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 1998. Abstract I-194. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15: F1-9.
19. Kosalaraksa P, Bunupuradah T, Engchanil C et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008; 27: 623-8.
20. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22: 1709-17.
21. Puthanakit T, Tanpaiboon P, Aurpibul L et al. Plasma efavirenz concentrations and the association with CYP2B6-516G.T polymorphism in HIV-infected Thai children. Antivir Ther 2009; 14: 315-20.
22. Estrela Rde C, Ribeiro FS, Barroso PF et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 2009; 10: 311-8.
23. Sáez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216-24.
24. Delaugerre C, Teglas JP, Treluyer JM et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2004; 37: 1269-75.
25. Chadwick EG, Capparelli EV, Yogev R et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22: 249-55.
26. Williams PL, Storm D, Montepiedra G et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006; 118: e1745-57.
27. van der Lugt J, Lange J, Avihingsanon A et al. Bioavailability of generic lopinavir/ritonavir in HIV-1 infected individuals. Antiviral Ther in press.